NLS Business article

In a region celebrated for gender equality, the life science sector tells a different story: women dominate the workforce in many jobs yet remain sidelined in leadership, funding, and research – with consequences that ripple across public health and economic performance.

The changes are a result of the divestment of Zubsolv in the US market and focus on advancing development programs and the AmorphOX technology.

In a nation that’s historically strong in tech, Finnish pharmaceutical development still struggles to capture the imagination of investors. The Finnish Drug Discovery Center sets out to help early-stage life science companies take their first steps towards investments and clinical development.

The European Life Sciences Coalition (ELSC) aims to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilizing greater levels of private and public investment across the sector.

This investment will expand medicines manufacturing and R&D in China and leverage the country’s scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations.

Lithuanian company Biomatter is an enzyme design company that bridges the gap between generative AI and real-world industrial applications.